Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sajjad Mahmood

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Eye (London, England)|March 22, 2022
The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practiceIan Pearce, Winfried Amoaku, Clare Bailey, et al.
Eye (London, England)|October 7, 2022
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panelClare Bailey, Peter Cackett, Ajay Kotagiri, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 30, 2017
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 updatePraveen J Patel, Helen Devonport, Sobha Sivaprasad, et al.
Eye (London, England)|January 5, 2020
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degenerationAdam H Ross, Louise Downey, Helen Devonport, et al.
Clinical Ophthalmology (Auckland, N.Z.)|September 22, 2018
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes GroupWinfried Amoaku, Konstantinos Balaskas, Tomas Cudrnak, et al.
Eye (London, England)|March 31, 2019
Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye serviceRichard P Gale, Sajjad Mahmood, Helen Devonport, et al.
Ophthalmology and Therapy|April 11, 2021
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert OpinionKonstantinos Balaskas, Winfried M Amoaku, Tomas Cudrnak, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Plos One|June 4, 2020
Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS studyPaul Mitchell, Tom G Sheidow, Michel E Farah, et al.
Ophthalmology. Retina|August 17, 2019
Direct Ophthalmic Healthcare Resource Use among Patients with Geographic Atrophy in a Large Cohort from the United KingdomUsha Chakravarthy, Clare C Bailey, Peter H Scanlon, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Eye (London, England)|March 22, 2022
The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practiceIan Pearce, Winfried Amoaku, Clare Bailey, et al.
Eye (London, England)|October 7, 2022
Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panelClare Bailey, Peter Cackett, Ajay Kotagiri, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 30, 2017
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 updatePraveen J Patel, Helen Devonport, Sobha Sivaprasad, et al.
Eye (London, England)|January 5, 2020
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degenerationAdam H Ross, Louise Downey, Helen Devonport, et al.
Clinical Ophthalmology (Auckland, N.Z.)|September 22, 2018
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes GroupWinfried Amoaku, Konstantinos Balaskas, Tomas Cudrnak, et al.
Eye (London, England)|March 31, 2019
Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye serviceRichard P Gale, Sajjad Mahmood, Helen Devonport, et al.
Ophthalmology and Therapy|April 11, 2021
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert OpinionKonstantinos Balaskas, Winfried M Amoaku, Tomas Cudrnak, et al.
Current Medical Research and Opinion|May 30, 2024
Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysisSobha Sivaprasad, Clare Bailey, Louise Downey, et al.
Plos One|June 4, 2020
Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS studyPaul Mitchell, Tom G Sheidow, Michel E Farah, et al.
Ophthalmology. Retina|August 17, 2019
Direct Ophthalmic Healthcare Resource Use among Patients with Geographic Atrophy in a Large Cohort from the United KingdomUsha Chakravarthy, Clare C Bailey, Peter H Scanlon, et al.
Pageof 4